Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Bosulif (bosutinib by Quarter
Bosulif (bosutinib — CML) — International reported YoY (%) (%)
Pfizer Bosulif (bosutinib: -24.0% in Q2 2026, up 10.0 pts from a year earlier.
Latest, Q2 2026
-24.0%
Period ended Jun 28, 2026
Change on a year earlier
+10.0 pts
-34.0% in Q2 2025
History
35 quarters
Since Q4 2017
Sources
35
Documents cited below
Where the Q2 2026 figure comes from
“|| Bosulif | 113 | 149 | (24%) | (24%) | 88 | 116 | (24%) | 25 | 32 | (24%) | (22%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Bosulif (bosutinib (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/bosulif-yoy-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.